Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avis Budget

61.95
+6.4611.64%
Post-market: 62.780.8320+1.34%19:43 EDT
Volume:2.11M
Turnover:126.99M
Market Cap:2.18B
PE:-1.21
High:63.18
Open:57.52
Low:55.69
Close:55.49
Loading ...

Avis Budget Group Inc - New Term Loan a Facility Established at $500 Million

THOMSON REUTERS
·
12 Feb

Avis Budget CEO Joe Ferraro to Step Down, Brian Choi Named Successor

Dow Jones
·
12 Feb

Avis Budget Group Q4 Swings to Loss, Revenue Declines -- Shares Down

MT Newswires Live
·
12 Feb

Avis Budget Gr Q4 Sales $2.71B Miss $2.72B Estimate

Benzinga
·
12 Feb

BRIEF-Avis Budget Q4 Net Income USD -1,958 Million

Reuters
·
12 Feb

Avis Budget Group Inc - Brian Choi to Become CEO Effective July 1, 2025

THOMSON REUTERS
·
12 Feb

Avis Budget Group Inc - Joe Ferraro to Transition From CEO to Board Advisor

THOMSON REUTERS
·
12 Feb

Avis Budget Group Reports Fourth Quarter and Full Year Results

GlobeNewswire
·
12 Feb

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
12 Feb

Avis Budget options imply 12.5% move in share price post-earnings

TIPRANKS
·
12 Feb

Morgans Financial Upgrades CAR Group to Add from Hold, Price Target is AU$41.40

MT Newswires Live
·
11 Feb

Morgan Stanley Reaffirms Their Buy Rating on CAR Group (WN6)

TIPRANKS
·
11 Feb

CAR Group's U.S. Guidance Isn't a Big Concern -- Market Talk

Dow Jones
·
11 Feb

CAR Group (WN6) Receives a Buy from Goldman Sachs

TIPRANKS
·
11 Feb

Immix Biopharma receives FDA RMAT designation for NCX-201 in r/r AL Amyloidosis

TIPRANKS
·
10 Feb

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

GlobeNewswire
·
10 Feb